title: Bcr-Abl tyrosine kinase inhibitors- current status.
abstract: Bcr-Abl plays a central role in the development of chromosome positive leukaemia. Chronic Myeloid leukaemia occurs due to increase proliferation and resistance to apoptosis by Bcr-Abl positive cells. Imatinib (STI571) is the first drug in the family of Bcr-Abl tyrosine kinase inhibitors while Nilotinib (AMN107) and Dasatinib (BMS-345825) are second generation drugs that are intended to have less resistance and intolerance than imatinib. Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase. 1, 3, 4 thiadiazole derivatives has also displayed moderate inhibitory action on both Abl and Src kinase family. However there are varieties of Bcr-Abl inhibitors but Nilotinib is still the frontline tyrosine kinase inhibitors.
authors.affiliation: Final Year Student Of Dinajpur Medical College, Dakshin Dinajpur District, West Bengal, Bangladesh. ribakumah@hotmail.com.
authors.forename: Anum
authors.initials: A
authors.lastname: Mughal
authors.forename: Hafiz Muhammad
authors.initials: HM
authors.lastname: Aslam
authors.forename: Aga Muhammad Hammad
authors.initials: AM
authors.lastname: Khan
authors.forename: Shafaq
authors.initials: S
authors.lastname: Saleem
authors.forename: Ribak
authors.initials: R
authors.lastname: Umah
authors.forename: Maria
authors.initials: M
authors.lastname: Saleem